# Tecentriq SC is now available across India with more than 100 patients already on immunotherapy.

*biotech · news · 2026-05-14 · Livemint*

## Key points

- Tecentriq SC, a subcutaneous lung cancer therapy, is now available across India after DCGI approval.
- The subcutaneous injection reduces administration time by 80%, allowing treatment in about seven minutes.
- Tecentriq SC's maximum retail price is ₹3.7 lakh per unit, higher than its IV version.
- Global clinical data shows 80% of patients preferred the subcutaneous version for comfort and reduced distress.
- If patients respond exceptionally well, Tecentriq SC therapy can be paused while patients remain stable.

**Companies:** Roche
**Countries:** India, United States, United Kingdom

[Read the full story on Livemint](https://www.livemint.com/news/roche-lung-cancer-immunotherapy-injection-pharma-healthcare-11778757287072.html)

---

Canonical: https://newsio.io/n/407df1d4-9d32-4426-bffa-305e0483a705/tecentriq-sc-is-now-available-across-india-with-more-than-100-patients-already-o
Summarized by Newsio from Livemint. https://newsio.io/how-it-works